ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,930.85
1.09%
Dow Jones
42,840.26
1.18%
US Dollar vs MXN
20.0813
0.00%
Brent Oil
72.72
0.00%
Bitcoin
97,132.09
-0.09%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX

  6. Channel Therapeutics Corporation (CHRO) Cotización

Channel Therapeutics Corporation

Channel Therapeutics Corporation (CHRO)

AMEX
0.6435
-0.0095
(-1.45%)
Cerrado 22 Diciembre 3:00PM
Delayed by 15 minutes
0.6203
-0.0232
(-3.61%)
Fuera de horario: 4:06PM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
0.6203
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
166,800
0.562 Rango del Día 0.65
0.45 Rango de 52 semanas 6.00
Capitalización de Mercado [m]
3.739M
Precio Anterior
0.653
Precio de Apertura
0.646
Hora
501
@
0.6435
Última hora de negociación
Volumen financiero
US$ 104,564
Precio Promedio Ponderado
0.62688
Volumen promedio (3 m)
161,435
Acciones en circulación
6,028,011
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.52
Beneficio por acción (BPA)
-1.22
turnover
-
Beneficio neto
-7.38M

Acerca de Channel Therapeutics Corporation

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. I... Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
channeltherapeutics.com
Sede
Reno, Nevada, USA
Fundado
-
Channel Therapeutics Corporation is listed in the Biological Pds,ex Diagnstics sector of the American Stock Exchange with ticker CHRO. The last closing price for Channel Therapeutics was US$0.65. Over the last year, Channel Therapeutics shares have traded in a share price range of US$ 0.45 to US$ 6.00.

Channel Therapeutics currently has 6,028,011 shares in issue. The market capitalisation of Channel Therapeutics is US$3.94 million. Channel Therapeutics has a price to earnings ratio (PE ratio) of -0.52.

CHRO Últimas noticias

Más noticias

Chromocell Announces Amendment to Stock Repurchase Plan

FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

24 Octubre 2024
GlobeNewswire Inc.

Chromocell to Participate in the Virtual Investor Lunch Break Series

FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

15 Julio 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

18 Junio 2024
Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]

15 Mayo 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

15 Mayo 2024
Edgar (US Regulatory)

Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024

FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

13 Mayo 2024
GlobeNewswire Inc.

Chromocell Issues Letter to Stockholders from Chief Executive Officer

FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

09 Abril 2024
GlobeNewswire Inc.

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

21 Marzo 2024
GlobeNewswire Inc.

Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023

FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

18 Marzo 2024
GlobeNewswire Inc.

Chromocell to Present at Sidoti Virtual Investor Conference March 13-14

AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...

11 Marzo 2024
GlobeNewswire Inc.
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.0691-10.02320858720.68940.68940.56332102990.59961457CS
40.00130.2100161550890.6190.880.55131638560.6990816CS
12-0.3496-36.04495308790.96991.040.451614350.73252942CS
26-0.7897-56.00709219861.411.750.45996750.80642223CS
52-5.3797-89.6616666667660.45691291.06548021CS
156-5.3797-89.6616666667660.45691291.06548021CS
260-5.3797-89.6616666667660.45691291.06548021CS

CHRO - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Channel Therapeutics?
El precio actual de las acciones de Channel Therapeutics es US$ 0.6203
¿Cuántas acciones de Channel Therapeutics están en circulación?
Channel Therapeutics tiene 6,028,011 acciones en circulación
¿Cuál es la capitalización de mercado de Channel Therapeutics?
La capitalización de mercado de Channel Therapeutics es USD 3.94M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Channel Therapeutics?
Channel Therapeutics ha negociado en un rango de US$ 0.45 a US$ 6.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Channel Therapeutics?
El ratio precio/beneficio de Channel Therapeutics es -0.52
¿Cuál es la moneda de reporte de Channel Therapeutics?
Channel Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Channel Therapeutics?
El último beneficio anual de Channel Therapeutics es USD -7.38M
¿Cuál es la dirección registrada de Channel Therapeutics?
La dirección registrada de Channel Therapeutics es 50 WEST LIBERTY STREET, SUITE 880, RENO, NEVADA, 89501
¿Cuál es la dirección del sitio web de Channel Therapeutics?
La dirección del sitio web de Channel Therapeutics es channeltherapeutics.com
¿En qué sector industrial opera Channel Therapeutics?
Channel Therapeutics opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MGLDMarygold Companies Inc
US$ 2.053
(48.77%)
128.45k
MINFT Limited
US$ 7.25
(44.22%)
948.89k
CTMCastellum Inc
US$ 0.578
(41.01%)
8.94M
KULRKULR Technology Group Inc
US$ 2.885
(28.79%)
75.72M
MSTUT Rex 2X Long MSTR Daily Target ETF
US$ 12.49
(22.81%)
64.96M
BATLBattalion Oil Corporation
US$ 1.3499
(-44.56%)
1.63M
NVOXDefiance Daily Target 2x Long Nvo ETF
US$ 11.5991
(-35.47%)
407.1k
UVIX2x Long VIX Futures ETF
US$ 3.83
(-29.07%)
70.61M
TPETTrio Petroleum Corp
US$ 1.10
(-25.17%)
2.81M
MSTZT Rex 2X Inverse MSTR Daily Target ETF
US$ 19.235
(-23.06%)
21.33M
SPYSPDR S&P 500
US$ 591.15
(0.86%)
122.49M
SPXSDirexion Daily S&P 500 Bear 3X Shares New
US$ 6.1628
(-3.25%)
114.87M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 27.30
(3.80%)
108.08M
TSLZT Rex 2X Inverse Tesla Daily Target ETF
US$ 2.435
(7.27%)
94.23M
KULRKULR Technology Group Inc
US$ 2.885
(28.79%)
75.72M

Discusión

Ver feed completo
Frankestin Frankestin 4 minutos hace
Just think, in July, when was this offer closed, it was at 0.50 and there was no 74 day letter imminent!
TNXP
ksquared ksquared 9 minutos hace
Wow! Great way to start the day. Thanks and GM, Bull.
walterc walterc 13 minutos hace
for your information

Jeunke is Dutch nott (lol) Belgian.
LWLG
ksquared ksquared 13 minutos hace
Good Morning, Mr. Gmenfancicle. We're in the tropics compared to you. We're still in double digits.
The joy of single ones arrives tonight. Fortunately we're due for a warm up on Tuesday.
To me, this snow was beautiful and easily managed. It lent the perfect atmo
Bull_Dolphin Bull_Dolphin 14 minutos hace
Tree topper:

https://x.com/KarluskaP/status/1870453214614892608
copytele copytele 16 minutos hace
https://youtu.be/QmJGGNZ06RY
RGTI
ksquared ksquared 19 minutos hace
GM, MG. So glad to read you got yourself a room with HEAT.
It's a frosty 14° up here in the NW corner of nj. Word has it we'll get up to a toasty 24 today and down to 4 tonight. Sleeping in your truck would be insanity.
Stay safe and warm.
Peter J Peter J 20 minutos hace
Mr. "beat around the bush" ...

.... looking out for the gullible investor here, on the, by it OTC Markets Group itself labelled "Buyer Beware!!" 'Skull and Bones' Expert market.

*There is no interest in ERHC, not even by insiders
*There is no possibility to buy t
ERHE
ksquared ksquared 26 minutos hace
Ana Kasparian of ‘Young Turks’ explodes at possibility of Harris becoming California governor: ‘I’m gonna move!’
By Alexander Hall, Fox News Published Dec. 21, 2024, 11:46 a.m. ET “This state cannot survive another incompetent Democrat leading it,” Kasparian said. “No, we just c
edbi46 edbi46 31 minutos hace
Lets see how high our beloved BIEL gets TRUMPed/JFK JUNIORed/DR. OZed up by Jan. 1, before NOPAIN Act is activated ( and, specifically, after!!! ) !!!!!

No WORD SALADS, no SUBSTANTIAL/NONE SUBSTANTIAL ACCUSATIONS, ( for like 13 years, from Oct. 2011 and counting?? ), did/will do any d
MCF WBA
Investor2014 Investor2014 32 minutos hace
Yes the centralised procedure on approval applies to all EU countries, but it is up to each country to decide whether and how to make an approved treatment available through their national healthcare system and negotiate pricing.
AVXL
Bull_Dolphin Bull_Dolphin 53 minutos hace
We restock during Easter sales. Shrink wrapped with our FoodSaver, they keep quite nicely.
jtaylor042 jtaylor042 1 hora hace
Well you're one who knows where the lifeboat is and...yet I still find you here.
NWBO
vuletini vuletini 1 hora hace
Built it and they will come....
SHIBUSD
jeunke22 jeunke22 1 hora hace
I have seen your recommendations across a number of boards. I am very aware of the risk involved when investing in start ups. Thanks for reminding me. I wil put you back where you belong! Bye bye!
LWLG
SteveSchiets SteveSchiets 2 horas hace
Yp, I know what to post to get your blood going. That's just a bit funny. I won't do it again. Of course you can post whatever you want.
This board is not swamped by newcomers, so I guess you don't have a lot of work. We are all adults here, no daily warnings is needed, imo.
I hold 7
SEV
biosectinvestor biosectinvestor 2 horas hace
Obviously not my point. You say stuff like this, yet either you never sell or you never really owned. Making noisy exits before they sell, for years, makes very little sense for real owners. Shorts and swing traders are frequently “exiting”,swing traders claim to do so, before news. And then want
NWBO
jeunke22 jeunke22 2 horas hace
Hope you understand that the $ 120 includes the PIC part in the transceiver market as well.
Conclusion: comparison with UDC between 40 and 120.
I will be happy with $ 40+ !
LWLG
LoveThemStocks LoveThemStocks 2 horas hace
I was told the same that you were told about falling in love with any subpenny and penny stock, but the reason for that is that many of the subpenny and penny stocks are scam companies. I'm in two companies right now that aren't scam stocks and both of them happens to be Tonix and Amprius. Tonix is
TNXP
TurboMountain96 TurboMountain96 2 horas hace
Osisko went for 4.90 a share, we are trading at 0.12 currently, say we sold at 1.50 a share worst ways I think we would love a 12x 😀
FFMGF
SilkRoad SilkRoad 2 horas hace
The difference is it is happening NOW.
KBLB
SilkRoad SilkRoad 2 horas hace
Your childish and antiquated arguments no longer match the current state of affairs. KBLB is well on its way to metric tonnage. 2025 will blow your mind. So get ready for it.
KBLB

Su Consulta Reciente

AMEX
CHRO
Channel Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados